The potential of PARP as a therapeutic target across pediatric solid malignancies.

ABSTRACT:

Background

Pediatric cancer is the leading cause of disease-related death in children and the need for better therapeutic options remains urgent. Due to the limited number of patients, target and drug development for pediatrics is often supplemented by data from studies focused on adult cancers. Recent evidence shows that pediatric cancers possess different vulnerabilities that should be explored independently from adult cancers.

Methods

Using the publicly available Genomics of Drug Sensitivity in Cancer database, we explore therapeutic targets and biomarkers specific to the pediatric solid malignancies Ewing sarcoma, medulloblastoma, neuroblastoma, osteosarcoma, and rhabdomyosarcoma. Results are validated using cell viability assays and high-throughput drug screens are used

SUBMITTER: Keller KM 

PROVIDER: S-EPMC10077757 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature